| Literature DB >> 23484158 |
Pornanong Aramwit1, Ouppatham Supasyndh, Tippawan Siritienthong, Nipaporn Bang.
Abstract
C-reactive protein (CRP) is the inflammatory marker that could represent the inflammation in blood vessels resulted from dyslipidemia. The objective of this study was to evaluate the antioxidative activity of mulberry leaf powder using DPPH assay and the effect of mulberry leaf powder on lipid profile, CRP level, and antioxidative parameters in mild dyslipidemia patients. A within-subjects design was conducted and patients received three tablets of 280 mg mulberry leaf powder three times a day before meals for 12 weeks. Total of 25 patients were enrolled but one subject was excluded. After three months of mulberry leaf consumption, serum triglyceride and low-density lipoprotein (LDL) level were significantly reduced and more than half of all patients' CRP levels decreased every month as well as the mean CRP level but no statistically significant difference was found. The average erythrocyte glutathione peroxidase activity of patients was increased but not at significant level; however, the mean serum 8-isoprostane level was significantly lower after mulberry treatment for 12 weeks. It can be concluded that mulberry leaf powder exhibited antioxidant activity and mulberry leaf powder has potential to decrease serum triglyceride, LDL, and CRP levels in mild dyslipidemia patients without causing severe adverse reactions.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23484158 PMCID: PMC3581086 DOI: 10.1155/2013/787981
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Figure 1IC50 of mulberry leaf extracts at room temperature.
Patient demographic characteristics and baseline laboratory data (n = 25).
| Characteristics | |
|---|---|
| Gender (M : F) | 5 : 20 |
| Age (years) | 35.88 ± 10.87 |
| Body mass index (kg/m2) | 23.18 ± 3.12 |
| Fasting plasma glucose (mg/dL) | 92.14 ± 6.72 |
| Alanine aminotransferase (U/L) | 18.42 ± 3.25 |
| Aspartate aminotransferase (U/L) | 17.44 ± 3.62 |
| Serum creatinine (mg/dL) | 0.62 ± 0.04 |
| Blood urea nitrogen (mg/dL) | 11.79 ± 2.73 |
| CVD risk factor (none : 1 risk) | 21 : 5 |
Serum lipid profile in patients with mild dyslipidemia after 12 weeks of treatment (n = 24).
| Mulberry leaf tablet therapy | |||
|---|---|---|---|
| Baseline | Week 12 | Change (%) | |
| Total cholesterol (mg/dL) | 216.3 ± 6.1 | 211.5 ± 4.3 | −1.8 |
| Triglyceride (mg/dL) | 114.2 ± 8.7 | 86.2 ± 7.4 | −10.6* |
| Low-density lipoprotein (mg/dL) | 163.7 ± 5.1 | 151.2 ± 3.8 | −8.2* |
| High-density lipoprotein (mg/dL) | 41.5 ± 3.4 | 45.3 ± 1.9 | +6.3 |
| TC : HDL | 5.6 ± 0.2 | 3.1 ± 0.3 | −6.4* |
TC: total cholesterol, HDL: high-density lipoprotein.
*P < 0.05 compared with the baseline.
Mean difference of CRP level and number of patients whose CRP level decreased comparing to baseline (month 0, after diet therapy) (n = 24).
| Duration | Mean difference of CRP level (mg/L) ± SD | Number of patients with decreased CRP (%) |
|---|---|---|
| Month 1–month 0 | −0.0175 ± 0.898 | 14 (58.33) |
| Month 2–month 0 | −0.1606 ± 1.201 | 14 (58.33) |
| Month 3–month 0 | −0.1753 ± 1.180 | 16 (66.67) |
Figure 2Mean CRP level of subjects in each month (n = 24).
Incidence of adverse reactions from the mulberry leaf powder treatment (n = 25).
| Adverse reactions | Number of patients (%) |
|---|---|
| Gastrointestinal | |
| Flatulence | 1 (4) |
| Diarrhea | 6 (24) |
| Constipation | 1 (4) |
| Miscellaneous | |
| Increase appetite | 2 (8) |
| Dizziness | 2 (8) |